Enzyme Regulation and Kinetics Study Guide

Organization of Multi-Enzyme Complexes and Substrate Channeling

• Multi-Enzyme Complexes:

  • In living cells, enzymes catalyzing consecutive steps (serial reactions) in metabolic pathways are frequently organized into non-covalently linked multi-enzyme complexes.

  • In a serial pathway ($A \rightarrow B \rightarrow C$), the product of the first enzymatic reaction serves directly as the substrate for the subsequent enzyme.

  • Pyruvate Dehydrogenase Complex Structure:

  • Composed of 3 distinct enzymatic activities organized into a giant macromolecular assembly:

    • 8 trimers of lipoamide reductase-transacetylase (24 catalytic subunits forming the core).

    • 6 dimers of dihydrolipoyl dehydrogenase (12 subunits).

    • 12 dimers of pyruvate decarboxylase (24 subunits).

• Substrate Channeling and Bypassing the Diffusion Limit:

  • Direct physical proximity between consecutive active sites enables substrate channeling, where intermediates pass directly from one active site to the next without fully equilibrating with the bulk aqueous cytoplasm.

  • Bypasses the limits imposed by simple molecular diffusion in solution.

  • Prevents side reactions, protects unstable intermediates, and substantially increases the overall metabolic rate of the cell.

• Molecular Tunnels in Multi-Active-Site Enzymes:

  • Some single enzymes have evolved multiple active sites connected internally by gas-tight or liquid-tight molecular tunnels.

  • Carbamoyl Phosphate Synthetase (CPS):

  • Catalyzes a multi-step reaction requiring three distinct active sites linked by an internal tunnel spanning long distances within the protein fold.

  • Reaction sequence:

    1. Glutamine is hydrolyzed at the first active site to generate ammonia ($NH_3$) and glutamate.

    2. Bicarbonate ($HCO_3^-$) is phosphorylated by ATP at a second active site to form carboxyphosphate.

    3. Ammonia travels through the internal molecular tunnel to react with carboxyphosphate, producing carbamic acid and inorganic phosphate ($P_i$).

    4. Carbamic acid travels further through the tunnel to a final active site where it is phosphorylated by a second ATP molecule to yield carbamoyl phosphate.

  • Functional Rationale:

    • Intermediates such as free ammonia ($NH_3$) are small, volatile, and toxic, while carboxyphosphate and carbamic acid are extremely unstable (labile) in cytoplasm and rapidly hydrolyze if released. The tunnel protects these intermediates and delivers them efficiently to the next catalytic site.

Reversible and Irreversible Enzyme Inhibition

• Irreversible Inhibition:

  • Inhibitors bind very tightly to the enzyme, either through covalent bonds or high-affinity non-covalent interactions.

  • The inhibitor dissociates extremely slowly from its target enzyme, permanently inactivating that enzyme molecule.

• Reversible Inhibition:

  • Characterized by rapid dissociation of the enzyme-inhibitor ($EI$) complex.

  • Subdivided into three main classes based on binding site and kinetic profile: competitive, uncompetitive, and non-competitive (or mixed) inhibition.

• Competitive Inhibition:

  • The inhibitor is a structural mimic of the natural substrate.

  • Competes directly with the substrate for binding to the enzyme's active site.

  • Binds only to free enzyme ($E$), not to the enzyme-substrate ($ES$) complex.

  • Equilibrium: $E + I \rightleftharpoons EI$

  • Kinetic Effects:

  • Increases the apparent $K_m$ ($K_m^{app} > K_m$), meaning higher substrate concentration is required to reach half-maximal velocity.

  • Does not change $V_{max}$: because the inhibitor and substrate compete for the same site, extremely high substrate concentrations compete out the inhibitor, allowing the enzyme to reach full saturation.

  • Mathematical Relationships:

  • $V_0 = \frac{V_{max} [S]}{K_m^{app} + [S]}$

  • $K_m^{app} = K_m \left(1 + \frac{[I]}{K_i}\right)$

  • $K_i = \frac{K_m [I]}{K_m^{app} - K_m}$

  • Lineweaver-Burk Plot:

  • Lines intersect directly on the y-axis ($1/V_{max}$ remains identical).

  • The slope ($\frac{K_m^{app}}{V_{max}}$) increases in the presence of inhibitor.

• Uncompetitive Inhibition:

  • The inhibitor binds only to the enzyme-substrate complex ($ES$) at an allosteric site formed after substrate binding; it cannot bind to free enzyme ($E$).

  • Equilibrium: $ES + I \rightleftharpoons ESI$

  • Kinetic Effects:

  • Decreases $V_{max}$ ($V_{max}^{app} < V_{max}$): formation of the inactive $ESI$ complex traps a fraction of the enzyme in a non-productive state, preventing catalysis regardless of how much substrate is added.

  • Decreases $K_m$ ($K_m^{app} < K_m$): binding of inhibitor to $ES$ depletes free $ES$, driving the $E + S \rightleftharpoons ES$ equilibrium to the right by Le Chatelier's principle, which manifests as an increased apparent affinity between enzyme and substrate.

  • The ratio $\frac{V_{max}}{K_m}$ remains unchanged ($\frac{V_{max}^{app}}{K_m^{app}} = \frac{V_{max}}{K_m}$).

  • Mathematical Relationships:

  • $V_{max}^{app} = \frac{V_{max}}{1 + \frac{[I]}{K_i}}$

  • $K_m^{app} = \frac{K_m}{1 + \frac{[I]}{K_i}}$

  • Lineweaver-Burk Plot:

  • Produces parallel lines with identical slopes ($\frac{K_m}{V_{max}}$) but elevated y-intercepts ($1/V_{max}^{app}$) and shifted x-intercepts ($-1/K_m^{app}$).

• Non-Competitive Inhibition:

  • The inhibitor binds to an allosteric site distinct from the active site.

  • Binds with equal affinity to both free enzyme ($E$) and the enzyme-substrate complex ($ES$).

  • Equilibria: $E + I \rightleftharpoons EI$ and $ES + I \rightleftharpoons ESI$ with identical dissociation constants ($K_i = K_i'$).

  • Inhibitor binding distorts the active site conformation, impairing catalytic efficiency without blocking substrate binding.

  • Kinetic Effects:

  • Decreases $V_{max}$ ($V_{max}^{app} < V_{max}$): a portion of enzyme is locked in inactive $EI$ or $ESI$ states.

  • $K_m$ remains unchanged ($K_m^{app} = K_m$): because the inhibitor binds free $E$ and $ES$ with equal affinity, it does not alter substrate binding affinity.

  • Mathematical Relationship:

  • $V_{max}^{app} = \frac{V_{max}}{1 + \frac{[I]}{K_i}}$

  • Lineweaver-Burk Plot:

  • Lines intersect directly on the x-axis ($-1/K_m$ remains constant), while the y-intercept ($1/V_{max}^{app}$) and slope increase.

• Mixed Inhibition:

  • The inhibitor binds to both free enzyme ($E$) and the $ES$ complex, but with different affinities ($K_i \neq K_i'$).

  • Alters both $V_{max}$ and $K_m$.

  • On a Lineweaver-Burk plot, the lines intersect at a point to the left of the y-axis, but not on the x-axis.

• Summary Table of Reversible Inhibitor Effects:

• Worked Kinetic Calculation Example:

  • Experimental dataset:

  • $[S]\,(\mu M)$: $0.20$, $0.26$, $0.33$, $1.00$

  • $1/[S]\,(\mu M^{-1})$: $5.00$, $3.85$, $3.03$, $1.00$

  • $V_0\,(\text{nmol/min})$ without inhibitor: $1.43$, $1.67$, $2.08$, $3.33$

  • $1/V_0\,(\text{min/nmol})$ without inhibitor: $0.70$, $0.60$, $0.48$, $0.30$

  • $V_0\,(\text{nmol/min})$ with inhibitor: $1.12$, $1.31$, $1.68$, $2.01$

  • $1/V_0\,(\text{min/nmol})$ with inhibitor: $0.89$, $0.76$, $0.59$, $0.50$

  • Analysis without inhibitor:

  • Plotting $1/V_0$ against $1/[S]$ yields a straight line.

  • Y-intercept: $\frac{1}{V_{max}} = 0.2\,\text{min/nmol} \implies V_{max} = 5.0\,\text{nmol/min}$.

  • X-intercept: $-\frac{1}{K_m} = -2.0\,\mu M^{-1} \implies K_m = 0.5\,\mu M$.

Five Principal Mechanisms of Enzyme Regulation

• Cellular Control Mechanisms:

  1. Allosteric Control: Reversible binding of regulatory molecules at sites distinct from the catalytic site inducing conformational changes.

  2. Reversible Covalent Modification: Addition or removal of specific chemical groups (e.g., phosphorylation by kinases, dephosphorylation by phosphatases).

  3. Multiple Forms of Enzymes (Isozymes): Synthesis of structurally distinct enzyme isoforms that catalyze the same reaction but display different kinetic properties and tissue locations.

  4. Proteolytic Activation: Irreversible activation of inactive enzyme precursors (zymogens) by selective peptide bond cleavage.

  5. Controlling the Amount of Enzyme Present: Adjusting overall enzyme concentrations via gene expression (transcription/translation) or targeted protein degradation.

Allosteric Control and Aspartate Transcarbamoylase (ATCase)

• Properties of Allosteric Proteins:

  • Proteins that exist in an equilibrium between two or more distinct conformational states.

  • Feature distinct catalytic (active) and regulatory (allosteric) binding sites that recognize different ligands (modulators).

  • Ligand binding at a regulatory site induces a conformational transition that alters the functional properties of catalytic sites.

  • Most rate-determining or committed steps in metabolic pathways are catalyzed by allosteric enzymes.

• Aspartate Transcarbamoylase (ATCase) Reaction:

  • Catalyzes the reaction between carbamoyl phosphate and aspartate to form $N$-carbamoylaspartate and inorganic phosphate ($P_i$).

  • Classified as a transferase (transfers a carbamoyl group to the $\alpha$-amino group of aspartate).

  • Represents the committed step in the biosynthesis of pyrimidine nucleotides, such as cytidine triphosphate (CTP).

• Feedback Inhibition of ATCase:

  • ATCase activity is negatively regulated by CTP, the final end-product of the pyrimidine biosynthetic pathway.

  • High CTP concentrations inhibit ATCase, reducing $N$-carbamoylaspartate synthesis.

  • Prevents overproduction of pyrimidines when intracellular pools are already sufficient.

  • In feedback regulation, the controlled step is nearly always the committed step, and the participating enzyme is an allosteric protein.

• Quaternary Structure of ATCase:

  • Total of 12 polypeptide chains organized into a multimeric complex:

  • 2 catalytic trimers: 6 catalytic subunits total, containing 6 distinct active sites.

  • 3 regulatory dimers: 6 regulatory subunits total, containing 6 distinct regulatory binding sites.

• T State vs. R State Conformational Equilibrium:

  • T State ("Tense"):

  • Low substrate affinity; active site is constrained and functionally inactive.

  • Stabilized by the allosteric inhibitor CTP.

  • R State ("Relaxed"):

  • High substrate affinity; active site is fully expanded and catalytically active.

  • Stabilized by substrate binding or by substrate analogs.

  • Structural Changes During Transition:

  • Binding of the bisubstrate analog $N$-(phosphonacetyl)-L-aspartate (PALA) triggers a structural change.

  • Catalytic trimers separate vertically along the threefold axis by $6\,\text{\AA}$ and rotate relative to each other by $10^\circ$.

  • Regulatory dimers rotate by $15^\circ$ around their twofold axes.

• Role of PALA in Structural Biology:

  • PALA ($N$-(phosphonacetyl)-L-aspartate) is a synthetic bisubstrate analog that combines structural features of both carbamoyl phosphate and aspartate.

  • Binds with high affinity to the active site and locks ATCase into the active R state, but cannot undergo chemical conversion to product.

  • Used by biochemists to freeze and crystallize the active R-state conformation for X-ray diffraction analysis.

• Sigmoidal Kinetics and Cooperativity:

  • Allosteric enzymes display sigmoidal (S-shaped) velocity vs. substrate concentration ($V_0$ vs. $[S]$) plots rather than hyperbolic Michaelis-Menten curves.

  • Homotropic Effects: The binding of a substrate molecule to one active site increases the affinity of remaining active sites on adjacent subunits (cooperativity).

  • Heterotropic Effects: Non-substrate effector molecules alter the T/R equilibrium:

  • CTP (inhibitor) stabilizes the T state, shifting the sigmoidal curve rightward (increasing $K_{0.5}$ / $K_m^{app}$).

  • ATP (activator) signals high purine levels, stabilizes the R state, and shifts the curve leftward toward hyperbolic behavior.

  • The sigmoidal curve represents a transition from a low-affinity ensemble (T state) to a high-affinity ensemble (R state) as substrate concentration increases.

Reversible Covalent Modification: Phosphorylation and Dephosphorylation

• Mechanism of Protein Phosphorylation:

  • Protein Kinases: Transfer the $\gamma$-phosphate group from ATP to the hydroxyl ($-OH$) group of specific amino acid side chains (Serine, Threonine, or Tyrosine).

  • Reaction: $\text{Protein-Ser-OH} + \text{ATP} \xrightarrow{\text{Protein Kinase}} \text{Protein-Ser-O-PO}_3^{2-} + \text{ADP}$

  • Protein Phosphatases: Remove phosphate groups via hydrolytic cleavage, regenerating the free hydroxyl side chain and releasing inorganic phosphate.

  • Reaction: $\text{Protein-Ser-O-PO}_3^{2-} + \text{H}_2\text{O} \xrightarrow{\text{Protein Phosphatase}} \text{Protein-Ser-OH} + \text{P}_i$

  • Phosphorylation introduces a bulky, doubly negative charge ($\text{-PO}_3^{2-}$) that forms new ionic interactions or disrupts existing electrostatic forces, switching enzyme activity on or off.

Isozymes: Functional Specialization of Enzyme Variants

• Isozymes (Isoenzymes):

  • Enzymes within the same organism that catalyze the identical chemical reaction but differ in amino acid sequence, kinetic constants ($K_m$, $V_{max}$), regulatory properties, and tissue localization.

• Case Study: Hexokinase vs. Glucokinase:

  • Both enzymes phosphorylate glucose to glucose-6-phosphate utilizing ATP.

  • Hexokinase:

  • Expressed in almost all non-hepatic tissues.

  • Possesses a low $K_m$ for glucose (high affinity); operates near maximal capacity even during low blood glucose conditions to ensure baseline cellular glycolysis.

  • Glucokinase:

  • Expressed specifically in the liver and pancreatic $\beta$-cells.

  • Possesses a high $K_m$ for glucose (low affinity).

  • Only active when blood glucose levels are abundant (e.g., post-meal), allowing the liver to trap excess glucose for glycogen storage without competing with peripheral tissues during fasting.

Proteolytic Activation and Protease Mechanisms

• Zymogens (Proenzymes):

  • Inactive precursor forms of enzymes activated by specific, irreversible cleavage of one or more peptide bonds.

  • Allows dangerous digestive enzymes or blood-clotting factors to be synthesized, stored, and transported safely in an inactive form prior to regulated physiological release.

• Gastric and Pancreatic Zymogens:

• Pancreatic Zymogen Activation Cascade:

  • Enteropeptidase (an enzyme embedded in the intestinal mucosa) cleaves trypsinogen specifically to generate active trypsin.

  • Trypsin then serves as the master activator for all other pancreatic zymogens, cleaving chymotrypsinogen, proelastase, procarboxypeptidase, and prolipase into their active forms, and autocatalytically cleaving additional trypsinogen molecules.

• Proteolytic Processing of Chymotrypsinogen:

  • Synthesized as a single, inactive polypeptide chain of 245 amino acids.

  • Trypsin cleaves the peptide bond between Arg 15 and Ile 16, producing an active intermediate called $\pi$-chymotrypsin.

  • $\pi$-chymotrypsin performs intermolecular cleavage on other $\pi$-chymotrypsin molecules, removing two dipeptide fragments (Ser 14–Arg 15 and Thr 147–Asn 148).

  • The resulting fully active, stable enzyme is $\alpha$-chymotrypsin, composed of 3 polypeptide chains (A chain [residues 1–13], B chain [residues 16–146], and C chain [residues 149–245]) held together by inter-chain disulfide bonds.

• Four Major Structural Classes of Proteases:

  • Serine Proteases: Utilize a reactive Serine residue as a covalent nucleophile. Contains a conserved catalytic triad: Serine (Ser 195), Histidine (His 57), and Aspartate (Asp 102). Examples: Chymotrypsin, Trypsin, Elastase.

  • Cysteine Proteases: Utilize a Cysteine residue as a nucleophile. Typically contain a catalytic dyad consisting of Cysteine (sulfhydryl, $-SH$) and Histidine. Example: Papain, Caspases.

  • Aspartyl Proteases: Rely on a pair of conserved Aspartate carboxyl groups working in concert to activate a water molecule into a nucleophile. Example: Pepsin, Renin, HIV Protease.

  • Metalloproteases: Utilize a tightly bound active-site metal ion (typically $Zn^{2+}$) coordinated by amino acid side chains to polarize and activate a water molecule for nucleophilic attack. Example: Carboxypeptidase A, Matrix Metalloproteinases (MMPs).

• Substrate Specificities of Serine Proteases:

  • Chymotrypsin: Contains a deep, hydrophobic binding pocket; selectively cleaves peptide bonds following large non-polar or aromatic residues (e.g., Phenylalanine, Tyrosine, Tryptophan).

  • Trypsin: Contains a deep pocket with a negatively charged Aspartate residue (Asp 189) at the bottom; selectively cleaves peptide bonds following long, positively charged basic residues (Lysine, Arginine).

  • Elastase: Binding pocket is constricted by bulky Valine residues (Val 190 and Val 216); selectively cleaves peptide bonds following small, uncharged hydrophobic residues (e.g., Alanine, Glycine, Serine).

Metabolic Pathway Regulation Strategies

• Regulation of Branched Biosynthetic Pathways:

  • Metabolic pathways often branch from a common intermediate to form multiple distinct end-products.

  • Objective: Ensure an adequate supply of all required terminal products while preventing wasteful accumulation of intermediates when end-product pools are sufficient.

• Purine Nucleotide Synthesis Regulation (AMP and GMP from R5P):

  • Reaction scheme: Ribose-5-phosphate (R5P) $\rightarrow A \rightarrow B \rightarrow C \rightarrow D \rightarrow E$

  • At intermediate $E$, the pathway branches into two distinct arms:

  • Arm 1: $E \rightarrow F \rightarrow G \rightarrow \text{AMP}$

  • Arm 2: $E \rightarrow H \rightarrow I \rightarrow \text{GMP}$

• Optimal Feedback Control Strategy:

  • Branch-Specific Feedback Inhibition:

  • AMP inhibits the enzyme catalyzing the first committed step of its own branch ($E \rightarrow F$).

  • GMP inhibits the enzyme catalyzing the first committed step of its own branch ($E \rightarrow H$).

  • Allows independent tuning of individual purine pools.

  • Synergistic / Concerted Early Inhibition:

  • AMP and GMP act synergistically to inhibit the initial committed step of the shared pathway ($\text{R5P} \rightarrow A$ or $A \rightarrow B$).

  • Shuts down upstream synthesis only when both AMP and GMP concentrations are high, preventing unnecessary buildup of intermediates $A$ through $E$.

  • Reciprocal Allosteric Activation:

  • ATP drives the conversion of $E$ to GMP, while GTP powers the conversion of $E$ to AMP.

  • Balances the relative production of adenine and guanine nucleotides.